1
|
Gao JP, Zhang HP, Wei R, Guo W. A Novel Method for the Rat Model of Abdominal Aortic Aneurysm Induced by Retroperitoneal Implantation of an Osmotic Pump System With Lipopolysaccharide. Ann Vasc Surg 2024; 101:41-52. [PMID: 38154490 DOI: 10.1016/j.avsg.2023.11.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 09/17/2023] [Accepted: 11/17/2023] [Indexed: 12/30/2023]
Abstract
BACKGROUND Few methods can cocurrently mimic the pathological characteristics and nature history of human abdominal aortic aneurysms (AAAs), especially for the exist of the self-healing tendency of rodents. This study tested a novel method for the AAA rat model induced by retroperitoneal implantation of an osmotic pump system with lipopolysaccharide (LPS) based on the hypothesis that chronic inflammation of perivascular adipose tissue directly influenced the development and progression of AAAs. METHODS 20 male Sprague-Dawley rats (10-month-old) fed with the Paigen diet were randomly divided into 4 groups: the blank group ×2, the sham group ×4, the empty capsule group ×4, and the LPS capsule group ×10. The LPS capsule group received implantations of the ALZET® osmotic pump capsule with LPS (3.6 μg/day) parallel to the abdominal aorta through a retroperitoneal approach. Two weeks later, 6 rats were randomly selected from the LPS capsule group to form the anti-inflammatory group and received implantations of another osmotic pump capsule with interleukin (IL)-10 (75 ng/day) through the same approach. The changes in abdominal aortic diameter were observed by ultrasound every 2 weeks, and samples were harvested for histopathologic and immunohistochemical analysis 6 weeks later. RESULTS Within the 6 weeks after modeling, the LPS capsule group showed sustained and significant aortic dilatation (P < 0.01), while the anti-inflammatory group showed a rapid and obvious shrinkage 2 weeks after the IL-10 osmotic pump capsule implantation (P < 0.01). The LPS capsule group presented excellent pathological mimicking of human AAAs and showed severe medial degeneration with the least elastic content among the 5 groups at the end of the sixth week (P < 0.05). Notably, the anti-inflammatory group showed perfect medial preservation with the most elastic content (P < 0.05) and the highest elastin/collagen ratio (P < 0.01) at the end of the study. Matrix metalloproteinases (MMP) 2 and 9 and toll-like receptor 2 showed strong expression in the LPS capsule group at the end of the sixth week, which was significantly higher than that in the blank group and sham group. Interestingly, the anti-inflammatory group showed a slightly higher MMP9 expression than the LPS capsule group though there was no statistical difference between them. CONCLUSIONS This novel method for the rat AAA model induced by retroperitoneal implantation of an osmotic pump capsule with LPS can concurrently mimic the histological characteristics and natural history of human AAAs. Further studies were needed to improve the osmotic pump system.
Collapse
Affiliation(s)
- Jiang-Ping Gao
- Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China; Medical School of Chinese PLA, Beijing, China
| | - Hong-Peng Zhang
- Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China
| | - Ren Wei
- Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China
| | - Wei Guo
- Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China.
| |
Collapse
|
2
|
Zeng H, Liang X, Roberts DA, Gillies ER, Müllner M. Self-Assembly of Rod-Coil Bottlebrush Copolymers into Degradable Nanodiscs with a UV-Triggered Self-Immolation Process. Angew Chem Int Ed Engl 2024; 63:e202318881. [PMID: 38320963 DOI: 10.1002/anie.202318881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 01/31/2024] [Accepted: 02/05/2024] [Indexed: 02/08/2024]
Abstract
Polymer nanodiscs, especially with stimuli-responsive features, represent an unexplored frontier in the nanomaterial landscape. Such 2D nanomaterials are considered highly promising for advanced biomedicine applications. Herein, we designed a rod-coil copolymer architecture based on an amphiphilic, tadpole-like bottlebrush copolymer, which can directly self-assemble into core-shell nanodiscs in an aqueous environment. As the bottlebrush side chains are made of amorphous, UV-responsive poly(ethyl glyoxylate) (PEtG) chains, they can undergo rapid end-to-end self-immolation upon light irradiation. This triggered nanodisc disassembly can be used to boost small molecule release from the nanodisc core, which is further aided by a morphological change from discs to spheres.
Collapse
Affiliation(s)
- Haoxiang Zeng
- Key Centre for Polymers and Colloids, School of Chemistry, The University of Sydney, 2006, Sydney, NSW, Australia
| | - Xiaoli Liang
- Department of Chemistry and Department of Chemical and Biochemical Engineering, The University of Western Ontario, N6A 5B7, London, Ontario, Canada
| | - Derrick A Roberts
- Key Centre for Polymers and Colloids, School of Chemistry, The University of Sydney, 2006, Sydney, NSW, Australia
| | - Elizabeth R Gillies
- Department of Chemistry and Department of Chemical and Biochemical Engineering, The University of Western Ontario, N6A 5B7, London, Ontario, Canada
| | - Markus Müllner
- Key Centre for Polymers and Colloids, School of Chemistry, The University of Sydney, 2006, Sydney, NSW, Australia
- The University of Sydney Nano Institute (Sydney Nano), The University of Sydney, 2006, Sydney, NSW, Australia
| |
Collapse
|
3
|
Ebrahimnia M, Alavi S, Vaezi H, Karamat Iradmousa M, Haeri A. Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment. EXCLI JOURNAL 2024; 23:143-179. [PMID: 38487087 PMCID: PMC10938236 DOI: 10.17179/excli2023-6747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/08/2024] [Indexed: 03/17/2024]
Abstract
Conventional cancer chemotherapy regimens, albeit successful to some extent, suffer from some significant drawbacks, such as high-dose requirements, limited bioavailability, low therapeutic indices, emergence of multiple drug resistance, off-target distribution, and adverse effects. The main goal of developing implantable drug delivery systems (IDDS) is to address these challenges and maintain anti-cancer drugs directly at the intended sites of therapeutic action while minimizing inevitable side effects. IDDS possess numerous advantages over conventional drug delivery, including controlled drug release patterns, one-time drug administration, as well as loading and stabilizing poorly water-soluble chemotherapy drugs. Here, we summarized conventional and novel (three-dimensional (3D) printing and microfluidic) preparation techniques of different IDDS, including nanofibers, films, hydrogels, wafers, sponges, and osmotic pumps. These systems could be designed with high biocompatibility and biodegradability features using a wide variety of natural and synthetic polymers. We also reviewed the published data on these systems in cancer therapy with a particular focus on their release behavior. Various release profiles could be attained in IDDS, which enable predictable, adjustable, and sustained drug releases. Furthermore, multi-step or stimuli-responsive drug release could be obtained in these systems. The studies mentioned in this article have proven the effectiveness of IDDS for treating different cancer types with high prevalence, including breast cancer, and aggressive cancer types, such as glioblastoma and liver cancer. Additionally, the challenges in applying IDDS for efficacious cancer therapy and their potential future developments are also discussed. Considering the high potential of IDDS for further advancements, such as programmable release and degradation features, further clinical trials are needed to ensure their efficiency. The overall goal of this review is to expand our understanding of the behavior of commonly investigated IDDS and to identify the barriers that should be addressed in the pursuit of more efficient therapies for cancer. See also the graphical abstract(Fig. 1).
Collapse
Affiliation(s)
- Maryam Ebrahimnia
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sonia Alavi
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA
| | - Hamed Vaezi
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahdieh Karamat Iradmousa
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Azadeh Haeri
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
4
|
Alghanem S, Dziurkowska E, Ordyniec-Kwaśnica I, Sznitowska M. Intraoral medical devices for sustained drug delivery. Clin Oral Investig 2023; 27:7157-7169. [PMID: 37982874 PMCID: PMC10713785 DOI: 10.1007/s00784-023-05377-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Accepted: 11/05/2023] [Indexed: 11/21/2023]
Abstract
OBJECTIVES The oral cavity constitutes an attractive organ for the local and systemic application of drug substances. Oromucosal tablets, gels, or sprays are examples of the formulations applied. Due to the elution through the saliva, the residence time of the formulation at the application site is relatively short. Medical devices placed in the oral cavity, with a reservoir for an active substance, play an important role in solving this problem. MATERIALS AND METHODS In this review, we discuss the devices described in the literature that are designed to be used in the oral cavity, highlighting the advantages, disadvantages, and clinical applications of each of them. RESULTS Among the intraoral medical devices, special types are personalized 3D-printed devices, iontophoretic devices, and microneedle patches. CONCLUSION We anticipate that with the development of 3D printing and new polymers, the technology of flexible and comfortable devices for prolonged drug delivery in the oral cavity will develop intensively. CLINICAL RELEVANCE The presented review is therefore a useful summary of the current technological state, when in fact none of the existing devices has been widely accepted clinically.
Collapse
Affiliation(s)
- Suhail Alghanem
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdansk, Poland
| | - Ewelina Dziurkowska
- Department of Analytical Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdansk, Poland.
| | - Iwona Ordyniec-Kwaśnica
- Department of Dental Prosthetics, Faculty of Medicine, Medical University of Gdansk, Str. E. Orzeszkowej 18, 80-208, Gdansk, Poland
| | - Małgorzata Sznitowska
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Al. Gen. J. Hallera 107, 80-416, Gdansk, Poland
| |
Collapse
|
5
|
Luo T, Zheng L, Chen D, Zhang C, Liu S, Jiang C, Xie Y, Du D, Zhou W. Implantable microfluidics: methods and applications. Analyst 2023; 148:4637-4654. [PMID: 37698090 DOI: 10.1039/d3an00981e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/13/2023]
Abstract
Implantable microfluidics involves integrating microfluidic functionalities into implantable devices, such as medical implants or bioelectronic devices, revolutionizing healthcare by enabling personalized and precise diagnostics, targeted drug delivery, and regeneration of targeted tissues or organs. The impact of implantable microfluidics depends heavily on advancements in both methods and applications. Despite significant progress in the past two decades, continuous advancements are still required in fluidic control and manipulation, device miniaturization and integration, biosafety considerations, as well as the development of various application scenarios to address a wide range of healthcare issues. In this review, we discuss advancements in implantable microfluidics, focusing on methods and applications. Regarding methods, we discuss progress made in fluid manipulation, device fabrication, and biosafety considerations in implantable microfluidics. In terms of applications, we review advancements in using implantable microfluidics for drug delivery, diagnostics, tissue engineering, and energy harvesting. The purpose of this review is to expand research ideas for the development of novel implantable microfluidic devices for various healthcare applications.
Collapse
Affiliation(s)
- Tao Luo
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
- The State Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou 310027, China
| | - Lican Zheng
- School of Aerospace Engineering, Xiamen University, Xiamen, 361102, China
| | - Dongyang Chen
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| | - Chen Zhang
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| | - Sirui Liu
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| | - Chongjie Jiang
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| | - Yu Xie
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| | - Dan Du
- School of Medicine, Xiamen University, Xiamen, 361102, China
| | - Wei Zhou
- Pen-Tung Sah Institute of Micro-Nano Science and Technology, Xiamen University, Xiamen, 361102, China.
| |
Collapse
|
6
|
Künzel SR, Winter L, Hoffmann M, Kant TA, Thiel J, Kronstein‐Wiedemann R, Klapproth E, Lorenz K, El‐Armouche A, Kämmerer S. Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice. Physiol Rep 2023; 11:e15809. [PMID: 37688424 PMCID: PMC10492006 DOI: 10.14814/phy2.15809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 08/18/2023] [Accepted: 08/18/2023] [Indexed: 09/10/2023] Open
Abstract
OBJECTIVES Myocardial infarction (MI) initiates a complex reparative response during which damaged cardiac muscle is replaced by connective tissue. While the initial repair is essential for survival, excessive fibrosis post-MI is a primary contributor to progressive cardiac dysfunction, and ultimately heart failure. Currently, there are no approved drugs for the prevention or the reversal of cardiac fibrosis. Therefore, we tested the therapeutic potential of repurposed mesalazine as a post-MI therapy, as distinct antifibrotic effects have recently been demonstrated. METHODS At 8 weeks of age, MI was induced in male C57BL/6J mice by LAD ligation. Mesalazine was administered orally at a dose of 100 μg/g body weight in drinking water. Fluid intake, weight development, and cardiac function were monitored for 28 days post intervention. Fibrosis parameters were assessed histologically and via qPCR. RESULTS Compared to controls, mesalazine treatment offered no survival benefit. However, no adverse effects on heart and kidney function and weight development were observed, either. While total cardiac fibrosis remained largely unaffected by mesalazine treatment, we found a distinct reduction of perivascular fibrosis alongside reduced cardiac collagen expression. CONCLUSIONS Our findings warrant further studies on mesalazine as a potential add-on therapy post-MI, as perivascular fibrosis development was successfully prevented.
Collapse
Affiliation(s)
- Stephan R. Künzel
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
- Institute of Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
- German Red Cross Blood Donation Service North‐EastDresdenGermany
| | - Luise Winter
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| | - Maximilian Hoffmann
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| | - Theresa A. Kant
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| | - Jessica Thiel
- Institute of Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
- German Red Cross Blood Donation Service North‐EastDresdenGermany
| | - Romy Kronstein‐Wiedemann
- Institute of Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
- German Red Cross Blood Donation Service North‐EastDresdenGermany
| | - Erik Klapproth
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| | - Kristina Lorenz
- Institute of Pharmacology and Toxicology, Julius‐Maximilians‐University of WürzburgWürzburgGermany
- Leibniz‐Institut für Analytische Wissenschaften ‐ISAS‐ e.VDortmundGermany
| | - Ali El‐Armouche
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| | - Susanne Kämmerer
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität DresdenDresdenGermany
| |
Collapse
|
7
|
Zhang C, Shao H, Han Z, Liu B, Feng J, Zhang J, Zhang W, Zhang K, Yang Q, Wu S. Development and In Vitro-In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease. Int J Mol Sci 2023; 24:12328. [PMID: 37569704 PMCID: PMC10418331 DOI: 10.3390/ijms241512328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/13/2023] Open
Abstract
This study aimed to develop extended-release tablets containing 25 mg IMM-H014, an original drug formulated by a direct powder pressing method based on pharmaceutical-grade hydrophilic matrix polymers such as hydroxypropyl methylcellulose, to establish an in vitro-in vivo correlation (IVIVC) to predict bioavailability. The tablets' mechanical properties and in vitro and in vivo performance were studied. The formulation was optimized using a single-factor experiment and the reproducibility was confirmed. The in vitro dissolution profiles of the tablet were determined in five dissolution media, in which the drug released from the hydrophilic tablets followed the Ritger-Peppas model kinetics in 0.01 N HCl medium for the first 2 h, and in phosphate-buffered saline medium (pH 7.5) for a further 24 h. Accelerated stability studies (40 °C, 75% relative humidity) proved that the optimal formulation was stable for 6 months. The in vivo pharmacokinetics study in beagle dogs showed that compared to the IMM-H014 immediate release preparation, the maximum plasma concentration of the extended-release (ER) preparation was significantly decreased, while the maximum time to peak and mean residence time were significantly prolonged. The relative bioavailability was 97.9% based on the area under curve, indicating that the optimal formulation has an obvious ER profile, and a good IVIVC was established, which could be used to predict in vivo pharmacokinetics based on the formulation composition.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Qingyun Yang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; (C.Z.); (H.S.); (Z.H.); (B.L.); (J.F.); (J.Z.); (W.Z.); (K.Z.)
| | - Song Wu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; (C.Z.); (H.S.); (Z.H.); (B.L.); (J.F.); (J.Z.); (W.Z.); (K.Z.)
| |
Collapse
|
8
|
Chan D, Maikawa CL, d’Aquino AI, Raghavan SS, Troxell ML, Appel EA. Polyacrylamide-based hydrogel coatings improve biocompatibility of implanted pump devices. J Biomed Mater Res A 2023; 111:910-920. [PMID: 36861657 PMCID: PMC10161736 DOI: 10.1002/jbm.a.37521] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 02/14/2023] [Accepted: 02/16/2023] [Indexed: 03/03/2023]
Abstract
The introduction of transcutaneous and subcutaneous implants and devices into the human body instigates fouling and foreign body responses (FBRs) that limit their functional lifetimes. Polymer coatings are a promising solution to improve the biocompatibility of such implants, with potential to enhance in vivo device performance and prolong device lifetime. Here we sought to develop novel materials for use as coatings on subcutaneously implanted devices to reduce the FBR and local tissue inflammation in comparison to gold standard materials such as poly(ethylene glycol) and polyzwitterions. We prepared a library of polyacrylamide-based copolymer hydrogels, which were selected from materials previously shown to exhibit remarkable antifouling properties with blood and plasma, and implanted them into the subcutaneous space of mice to evaluate their biocompatibility over the course of 1 month. The top performing polyacrylamide-based copolymer hydrogel material, comprising a 50:50 mixture of N-(2-hydroxyethyl)acrylamide (HEAm) and N-(3-methoxypropyl)acrylamide (MPAm), exhibited significantly better biocompatibility and lower tissue inflammation than gold standard materials. Moreover, when applied to polydimethylsiloxane disks or silicon catheters as a thin coating (45 ± 1 μm), this leading copolymer hydrogel coating significantly improved implant biocompatibility. Using a rat model of insulin-deficient diabetes, we showed that insulin pumps fitted with HEAm-co-MPAm hydrogel-coated insulin infusion catheters exhibited improved biocompatibility and extended functional lifetime over pumps fitted with industry standard catheters. These polyacrylamide-based copolymer hydrogel coatings have the potential to improve device function and lifetime, thereby reducing the burden of disease management for people regularly using implanted devices.
Collapse
Affiliation(s)
- Doreen Chan
- Department of Chemistry, Stanford University, Stanford, CA 94305
- Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305
| | - Caitlin L. Maikawa
- Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305
- Department of Bioengineering, Stanford University, Stanford, CA 94305
| | - Andrea I. d’Aquino
- Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305
| | - Shyam S. Raghavan
- Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305
| | - Megan L. Troxell
- Department of Pathology, University of Virginia, Charlottesville, VA, 22902
| | - Eric A. Appel
- Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305
- Department of Bioengineering, Stanford University, Stanford, CA 94305
- Department of Pediatrics (Endocrinology), Stanford University School of Medicine, Stanford, CA 94305
- Woods Institute for the Environment, Stanford University, Stanford, CA 94305
- ChEM-H Institute, Stanford University, Stanford, CA 94305
| |
Collapse
|
9
|
Hong JY, Kim H, Lee J, Jeon WJ, Yeo C, Kim H, Lee YJ, Ha IH. Epidural Injection Method for Long-Term Pain Management in Rats with Spinal Stenosis. Biomedicines 2023; 11:biomedicines11051390. [PMID: 37239061 DOI: 10.3390/biomedicines11051390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 04/24/2023] [Accepted: 05/05/2023] [Indexed: 05/28/2023] Open
Abstract
Epidural injection is one of the most common nonsurgical treatment options for long-term pain relief in lumbar spinal stenosis. Recently, various nerve block injections have been used for pain management. Among them, nerve block through epidural injection is a safe and effective method for the clinical treatment of low back or lower extremity pain. Although the epidural injection method has a long history, the effectiveness of long-term epidural injections in disc diseases has not been scientifically proven. In particular, to verify the safety and efficacy of drugs in preclinical studies, the route and method of drug administration in terms of the clinical application method and duration of use must be established. However, there is no standardized method for long-term epidural injections in a rat model of stenosis to identify the precise efficacy and safety of epidural injections. Therefore, standardizing the epidural injection method is very important for evaluating the efficacy and safety of drugs used for back or lower extremity pain. We describe the first standardized long-term epidural injection method for evaluating the efficacy and safety of drugs according to their route of administration in rats with lumbar spinal stenosis.
Collapse
Affiliation(s)
- Jin Young Hong
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Hyunseong Kim
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Junseon Lee
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Wan-Jin Jeon
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Changhwan Yeo
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Hyun Kim
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - Yoon Jae Lee
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| | - In-Hyuk Ha
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 135-896, Republic of Korea
| |
Collapse
|
10
|
Almoshari Y. Osmotic Pump Drug Delivery Systems-A Comprehensive Review. Pharmaceuticals (Basel) 2022; 15:1430. [PMID: 36422560 PMCID: PMC9697821 DOI: 10.3390/ph15111430] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 11/03/2022] [Accepted: 11/05/2022] [Indexed: 07/22/2023] Open
Abstract
In the last couple of years, novel drug delivery systems (NDDS) have attracted much attention in the food and pharmaceutical industries. NDDS is a broad term that encompasses many dosage forms, one of which is osmotic pumps. Osmotic pumps are considered to be the most reliable source of controlled drug delivery, both in humans and in animals. These pumps are osmotically controlled and release active agents through osmotic pressure. To a large extent, drug release from such a system is independent of gastric fluids. Based on such unique properties and advantages, osmotic pumps have made their mark on the pharmaceutical industry. This review summarizes the available osmotic devices for implantation and osmotic tablets for oral administration.
Collapse
Affiliation(s)
- Yosif Almoshari
- The Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia
| |
Collapse
|
11
|
Kumar R, Chauhan S. Cellulose nanocrystals based delivery vehicles for anticancer agent curcumin. Int J Biol Macromol 2022; 221:842-864. [PMID: 36100000 DOI: 10.1016/j.ijbiomac.2022.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/21/2022] [Accepted: 09/08/2022] [Indexed: 11/05/2022]
Abstract
Cancer is a complex disease that starts with genetic alterations and mutations in healthy cells. The past decade has witnessed a huge demand for new biocompatibility and high-performance intelligent drug delivery systems. Curcumin (CUR) is a bioactive stimulant with numerous medical benefits. However, because of its hydrophobic nature, it has low bioavailability. The utilization of many biobased materials has been found to improve the loading of hydrophobic drugs. Cellulose nanocrystals (CNCs) with exceptional qualities and a wide range of applications, feature strong hydrophilicity and lipophilicity, great emulsification stability, high crystallinity and outstanding mechanical attributes. In this review, numerous CNCs-based composites have been evaluated for involvement in the controlled release of CUR. The first part of the review deals with recent advancements in the extraction of CNCs from lignocellulose biomass. The second elaborates some recent developments in the post-processing of CNCs in conjunction with other materials like natural polymers, synthetic polymers, β-CD, and surfactants for CUR loading/encapsulation and controlled release. Furthermore, numerous CUR drug delivery systems, challenges, and techniques for effective loading/encapsulation of CUR on CNCs-based composites have been presented. Finally, conclusions and future outlooks are also explored.
Collapse
Affiliation(s)
- Rajesh Kumar
- Department of Chemistry, Jagdish Chandra DAV College, Dasuya, Punjab 144205, India.
| | - Sandeep Chauhan
- Department of Chemistry, Himachal Pradesh University, Summer Hill, Shimla, 171005, India
| |
Collapse
|
12
|
Rajan R, Pal K, Jayadev D, Jayan JS, U A, Appukuttan S, de Souza FG, Joseph K, Kumar SS. Polymeric Nanoparticles in Hybrid Catalytic Processing and Drug Delivery System. Top Catal 2022. [DOI: 10.1007/s11244-022-01697-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Li W, Meng J, Ma X, Lin J, Lu X. Advanced materials for the delivery of vaccines for infectious diseases. BIOSAFETY AND HEALTH 2022. [DOI: 10.1016/j.bsheal.2022.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
14
|
Bacchin P, Leng J, Salmon JB. Microfluidic Evaporation, Pervaporation, and Osmosis: From Passive Pumping to Solute Concentration. Chem Rev 2021; 122:6938-6985. [PMID: 34882390 DOI: 10.1021/acs.chemrev.1c00459] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Evaporation, pervaporation, and forward osmosis are processes leading to a mass transfer of solvent across an interface: gas/liquid for evaporation and solid/liquid (membrane) for pervaporation and osmosis. This Review provides comprehensive insight into the use of these processes at the microfluidic scales for applications ranging from passive pumping to the screening of phase diagrams and micromaterials engineering. Indeed, for a fixed interface relative to the microfluidic chip, these processes passively induce flows driven only by gradients of chemical potential. As a consequence, these passive-transport phenomena lead to an accumulation of solutes that cannot cross the interface and thus concentrate solutions in the microfluidic chip up to high concentration regimes, possibly up to solidification. The purpose of this Review is to provide a unified description of these processes and associated microfluidic applications to highlight the differences and similarities between these three passive-transport phenomena.
Collapse
Affiliation(s)
- Patrice Bacchin
- Laboratoire de Génie Chimique, Université de Toulouse, CNRS, INPT, UPS, 31000 Toulouse, France
| | - Jacques Leng
- CNRS, Solvay, LOF, UMR 5258, Université de Bordeaux, 33600 Pessac, France
| | | |
Collapse
|
15
|
Rasouli M, Fallah N, Bekeschus S. Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021; 2021:2990326. [PMID: 34745414 PMCID: PMC8566074 DOI: 10.1155/2021/2990326] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 09/28/2021] [Accepted: 09/30/2021] [Indexed: 02/07/2023]
Abstract
Nanomedicine and plasma medicine are innovative and multidisciplinary research fields aiming to employ nanotechnology and gas plasma to improve health-related treatments. Especially cancer treatment has been in the focus of both approaches because clinical response rates with traditional methods that remain improvable for many types of tumor entities. Here, we discuss the recent progress of nanotechnology and gas plasma independently as well as in the concomitant modality of nanoplasma as multimodal platforms with unique capabilities for addressing various therapeutic issues in oncological research. The main features, delivery vehicles, and nexus between reactivity and therapeutic outcomes of nanoparticles and the processes, efficacy, and mechanisms of gas plasma are examined. Especially that the unique feature of gas plasma technology, the local and temporally controlled deposition of a plethora of reactive oxygen, and nitrogen species released simultaneously might be a suitable additive treatment to the use of systemic nanotechnology therapy approaches. Finally, we focus on the convergence of plasma and nanotechnology to provide a suitable strategy that may lead to the required therapeutic outcomes.
Collapse
Affiliation(s)
- Milad Rasouli
- Plasma Medicine Group, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Jalale-Al-Ahmad Ave, 1411713137 Tehran, Iran
- Department of Physics and Institute for Plasma Research, Kharazmi University, 49 Dr. Mofatteh Ave, Tehran 15614, Iran
| | - Nadia Fallah
- Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, 49 Dr. Mofatteh Ave, 31979-37551 Tehran, Iran
| | - Sander Bekeschus
- ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany
| |
Collapse
|
16
|
Ogueri KS, Shamblin SL. Osmotic-controlled release oral tablets: technology and functional insights. Trends Biotechnol 2021; 40:606-619. [PMID: 34689998 DOI: 10.1016/j.tibtech.2021.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 09/30/2021] [Accepted: 10/01/2021] [Indexed: 12/20/2022]
Abstract
In recent years, oral osmotic tablets have sparked a therapeutic paradigm for controlled-release dosage forms due to their intrinsic insensitivity to physiological and physicochemical factors. Despite these benefits, the design of an optimal osmotic technology is precluded by various challenges. These limitations include manufacturing complexity, the lack of understanding of the functional mechanics, and inadequate optimization for the desired bio-performance. This paper systematically reviews the development of an osmotic-driven drug delivery system and the strategy for a zero-order release profile with an emphasis on swellable core technology. We discuss the applicability of the various types of osmotic tablets, their suitability to specific needs, and factors that drive the technology selection. Finally, we review the challenges, opportunities, and future perspectives associated with osmotic tablets.
Collapse
|
17
|
Tharmatt A, Malhotra D, Sharma H, Bedi N. Pharmaceutical Perspective in Wearable Drug Delivery Systems. Assay Drug Dev Technol 2021; 19:386-401. [PMID: 34339259 DOI: 10.1089/adt.2021.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Humans have been dealing with health problems for millions of years. Normal health services need well-trained personnel and high-cost diagnostic tests, which forces patients to go to hospitals if medical treatment is required. To address this, prototype testing has been carried out into the wearable drug delivery health care perspectives. Researchers have devised a wide variety of formulations for the treatment of various diseases at home by performing real-time monitoring of different routes of drug administration such as ocular, transdermal, intraoral, intracochlear, and several more. A comprehensive review of the different types of wearable drug delivery systems with respect to their manufacturing, mechanism of action and specifications has been done. In the pharmaceutical context, these devices are technologically well-equipped interfaces for diverse physicochemical signals. Above mentioned information with a broader perspective has also been discussed in this article. Several wearable drug delivery systems have been introduced in the market in recent years. But a lot of testing needs to be conducted to address the numerous obstacles before the wearable devices are successfully launched in the market.
Collapse
Affiliation(s)
- Abhay Tharmatt
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India
| | - Danish Malhotra
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India
| | - Hamayal Sharma
- Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Pilani, India
| | - Neena Bedi
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India
| |
Collapse
|
18
|
Liu Y, Sun L, Zhang H, Shang L, Zhao Y. Microfluidics for Drug Development: From Synthesis to Evaluation. Chem Rev 2021; 121:7468-7529. [PMID: 34024093 DOI: 10.1021/acs.chemrev.0c01289] [Citation(s) in RCA: 72] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Drug development is a long process whose main content includes drug synthesis, drug delivery, and drug evaluation. Compared with conventional drug development procedures, microfluidics has emerged as a revolutionary technology in that it offers a miniaturized and highly controllable environment for bio(chemical) reactions to take place. It is also compatible with analytical strategies to implement integrated and high-throughput screening and evaluations. In this review, we provide a comprehensive summary of the entire microfluidics-based drug development system, from drug synthesis to drug evaluation. The challenges in the current status and the prospects for future development are also discussed. We believe that this review will promote communications throughout diversified scientific and engineering communities that will continue contributing to this burgeoning field.
Collapse
Affiliation(s)
- Yuxiao Liu
- Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.,State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
| | - Lingyu Sun
- Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.,State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
| | - Hui Zhang
- Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.,State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
| | - Luoran Shang
- Zhongshan-Xuhui Hospital, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China
| | - Yuanjin Zhao
- Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.,State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China
| |
Collapse
|
19
|
Bott KN, Yumol JL, Comelli EM, Klentrou P, Peters SJ, Ward WE. Trabecular and cortical bone are unaltered in response to chronic lipopolysaccharide exposure via osmotic pumps in male and female CD-1 mice. PLoS One 2021; 16:e0243933. [PMID: 33544708 PMCID: PMC7864436 DOI: 10.1371/journal.pone.0243933] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 11/30/2020] [Indexed: 12/05/2022] Open
Abstract
Chronic low-grade inflammation has been identified as an underlying cause of many diseases including osteoporosis. Lipopolysaccharide (LPS) is a potent inducer of the inflammatory response that can negatively affect bone outcomes by upregulating bone resorption and inhibiting bone formation. The objective of this study was to assess the longitudinal response of trabecular and cortical bone structure and bone mineral density to LPS continuously administered for 12 weeks in male and female CD-1 mice. Mice were assigned to one of four LPS groups at 8-weeks of age: placebo (0.0 μg/d), low (0.9 μg/d), mid (3.6 μg/d) and high (14.4 μg/d) dose. Trabecular and cortical bone outcomes were measured at 8, 12, 16, and 20 weeks of age using in vivo micro-computed tomography. The anticipated serum LPS dose-dependent response was not observed. Therefore, the low, mid, and high LPS groups were combined for analysis. Compared to the placebo group, endpoint serum LPS was elevated in both males (p < 0.05) and females (p < 0.05) when all LPS treatment groups were combined. However, there was no significant change in trabecular or cortical bone outcomes in the combined LPS groups compared to the placebo following the 12-week LPS intervention for either sex. This suggests that although serum LPS was elevated following the 12-week LPS intervention, the dosages administered using the osmotic pumps was not sufficient to negatively impact trabecular or cortical bone outcomes in either male or female CD-1 mice.
Collapse
Affiliation(s)
- Kirsten N. Bott
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
- * E-mail:
| | - Jenalyn L. Yumol
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
| | - Elena M. Comelli
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
- Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada
- Joannah and Brian Lawson Centre for Child Nutrition, University of Toronto, Toronto, ON, Canada
| | - Panagiota Klentrou
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
- Centre for Bone and Muscle Health, Brock University, St. Catharines, ON, Canada
| | - Sandra J. Peters
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
- Centre for Bone and Muscle Health, Brock University, St. Catharines, ON, Canada
| | - Wendy E. Ward
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada
- Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada
- Centre for Bone and Muscle Health, Brock University, St. Catharines, ON, Canada
- Department of Health Sciences, Brock University, St. Catharines, ON, Canada
| |
Collapse
|
20
|
Fukuba T, Fujii T. Lab-on-a-chip technology for in situ combined observations in oceanography. LAB ON A CHIP 2021; 21:55-74. [PMID: 33300537 DOI: 10.1039/d0lc00871k] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The oceans sustain the global environment and diverse ecosystems through a variety of biogeochemical processes and their complex interactions. In order to understand the dynamism of the local or global marine environments, multimodal combined observations must be carried out in situ. On the other hand, instrumentation of in situ measurement techniques enabling biological and/or biochemical combined observations is challenging in aquatic environments, including the ocean, because biochemical flow analyses require a more complex configuration than physicochemical electrode sensors. Despite this technical hurdle, in situ analyzers have been developed to measure the concentrations of seawater contents such as nutrients, trace metals, and biological components. These technologies have been used for cutting-edge ocean observations to elucidate the biogeochemical properties of water mass with a high spatiotemporal resolution. In this context, the contribution of lab-on-a-chip (LoC) technology toward the miniaturization and functional integration of in situ analyzers has been gaining momentum. Due to their mountability, in situ LoC technologies provide ideal instrumentation for underwater analyzers, especially for miniaturized underwater observation platforms. Consequently, the appropriate combination of reliable LoC and underwater technologies is essential to realize practical in situ LoC analyzers suitable for underwater environments, including the deep sea. Moreover, the development of fundamental LoC technologies for underwater analyzers, which operate stably in extreme environments, should also contribute to in situ measurements for public or industrial purposes in harsh environments as well as the exploration of the extraterrestrial frontier.
Collapse
Affiliation(s)
- Tatsuhiro Fukuba
- Institute for Marine-Earth Exploration and Engineering, Japan Agency for Marine-Earth Science and Technology, Natsushima-cho 2-15, Yokosuka, Kanagawa 237-0061, Japan.
| | | |
Collapse
|
21
|
Jana P, Shyam M, Singh S, Jayaprakash V, Dev A. Biodegradable polymers in drug delivery and oral vaccination. Eur Polym J 2021. [DOI: 10.1016/j.eurpolymj.2020.110155] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
22
|
Rezvani Alanagh H, Rostami I, Taleb M, Gao X, Zhang Y, Khattak AM, He X, Li L, Tang Z. Covalent organic framework membrane for size selective release of small molecules and peptide in vitro. J Mater Chem B 2020; 8:7899-7903. [PMID: 32845948 DOI: 10.1039/d0tb01416h] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The ability to control small drug release is crucial in biomedicine, especially for inhibiting the side effects of drugs, but it is still challenging. Herein, to mimic the controlled release of drugs, the release of organic molecules, e.g., small organic dyes and peptides, through Covalent Organic Framework (COF) membranes with ordered nanoscale pores has been investigated, showing constant zero-order release behaviours. Meanwhile, biological assessments show the good biocompatibility of the COF membrane-based release system, and the high stability of the COF membrane was manifested by the long-term release of small molecules in aqueous media.
Collapse
Affiliation(s)
- Hamideh Rezvani Alanagh
- CAS Key Laboratory of Nanosystem and Hierarchical Fabrication, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P. R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Wang S, Liu R, Fu Y, Kao WJ. Release mechanisms and applications of drug delivery systems for extended-release. Expert Opin Drug Deliv 2020; 17:1289-1304. [PMID: 32619149 DOI: 10.1080/17425247.2020.1788541] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Drug delivery systems with extended-release profiles are ideal in improving patient compliance with enhanced efficacy. To develop devices capable of a prolonged delivery kinetics, it is crucial to understand the various underlying mechanisms contributing to extended drug release and the impact thereof on modulating the long-term performance of such systems in a practical application environment. AREAS COVERED This review article intends to provide a comprehensive summary of release mechanisms in extended-release drug delivery systems, particularly polymer-based systems; however, other material types will also be mentioned. Selected current research in the delivery of small molecule drugs and macromolecules is highlighted. Emphasis is placed on the combined impact of different release mechanisms and drug properties on the long-term release kinetics in vitro and in vivo. EXPERT OPINION The development of drug delivery systems over an extended duration is promising but also challenging when considering the numerous interrelated delivery-related parameters. Achieving a well-controlled extended drug release requires advanced techniques to minimize burst release and lag phase, a better understanding of the dynamic interrelationship between drug properties and release profiles over time, and a thorough elucidation of the impact of multiple in vivo conditions to methodically evaluate the eventual clinical efficacy.
Collapse
Affiliation(s)
- Shuying Wang
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University , Chengdu, China
| | - Renhe Liu
- Global Health Drug Discovery Institute , Beijing, China
| | - Yao Fu
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University , Chengdu, China
| | - W John Kao
- Department of Industrial and Manufacturing Systems Engineering, Biomedical Engineering Programme, Chemical Biology Centre, and Li Ka Shing Faculty of Medicine, The University of Hong Kong , Pokfulam, China
| |
Collapse
|
24
|
Khan AM, Hanif M, Bukhari NI, Shamim R, Rasool F, Rasul S, Shafique S. Artificial Neural Network (ANN) Approach to Predict an Optimized pH-Dependent Mesalamine Matrix Tablet. DRUG DESIGN DEVELOPMENT AND THERAPY 2020; 14:2435-2448. [PMID: 32606610 PMCID: PMC7320029 DOI: 10.2147/dddt.s244016] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 04/27/2020] [Indexed: 01/04/2023]
Abstract
Background Severe bleeding and perforation of the colon and rectum are complications of ulcerative colitis which can be treated by a targeted drug delivery system. Purpose Development of colon-targeted delivery usually involves a complex formulation process and coating steps of pH-sensitive methacrylic acid based Eudragit®. The current work was purposefully designed to develop dicalcium phosphate (DCP) facilitated with Eudragit-S100-based pH-dependent, uncoated mesalamine matrix tablets. Materials and Methods Mesalamine formulations were compressed using wet granulation technique with varying compositions of dicalcium phosphate (DCP) and Eudragit-S100. The developed formulations were characterized for physicochemical and drug release profiles. Infrared studies were carried out to ensure that there was no interaction between active ingredients and excipients. Artificial neural network (ANN) was used for the optimization of final DCP-Eudragit-S100 complex and the experimental data were employed to train a multi-layer perception (MLP) using quick propagation (QP) training algorithm until a satisfactory root mean square error (RMSE) was reached. The ANN-aided optimized formulation was compared with commercially available Masacol®. Results Compressed tablets met the desirability criteria in terms of thickness, hardness, weight variation, friability, and content uniformity, ie, 5.34 mm, 7.7 kg/cm2, 585±5 mg (%), 0.44%, and 103%, respectively. In-vitro dissolution study of commercially available mesalamine and optimized formulation was carried out and the former showed 100% release at 6 h while the latter released only 12.09% after 2 h and 72.96% after 12 h which was fitted to Weibull release model with b value of 1.3, indicating a complex release mechanism. Conclusion DCP-Eudragit-S100 blend was found explicative for mesalamine release without coating in gastric and colonic regions. This combination may provide a better control of ulcerative colitis. ![]()
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/AP32Kh16ZpU
Collapse
Affiliation(s)
- Asad Majeed Khan
- Faculty of Pharmacy, Bahauddin Zakriya University, Multan, Pakistan.,Lahore Pharmacy College, Lahore Medical and Dental College, Lahore, Pakistan
| | - Muhammad Hanif
- Faculty of Pharmacy, Bahauddin Zakriya University, Multan, Pakistan
| | | | - Rahat Shamim
- University College of Pharmacy, University of the Punjab, Lahore, Pakistan
| | - Fatima Rasool
- University College of Pharmacy, University of the Punjab, Lahore, Pakistan
| | - Sumaira Rasul
- Institute of Molecular Biology and Biotechnology, Bahauddin Zakriya University, Multan, Pakistan
| | - Sana Shafique
- Faculty of Pharmacy, Rippha International University, Lahore, Pakistan
| |
Collapse
|
25
|
Park HW, Park CG, Park M, Lee SH, Park HR, Lim J, Paek SH, Choy YB. Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson's disease rat model. Sci Rep 2020; 10:9572. [PMID: 32533070 PMCID: PMC7293316 DOI: 10.1038/s41598-020-66493-w] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Accepted: 05/18/2020] [Indexed: 12/12/2022] Open
Abstract
Parkinson's disease is a neurodegenerative disorder, and no treatment has been yet established to prevent disease progression. Coenzyme Q10, an antioxidant, has been considered a promising neuroprotective agent; however, conventional oral administration provides limited efficacy due to its very low bioavailability. In this study, we hypothesised that continuous, intrastriatal administration of a low dose of Coenzyme Q10 could effectively prevent dopaminergic neuron degeneration. To this end, a Parkinson's disease rat model induced by 6-hydroxydopamine was established, and the treatment was applied a week before the full establishment of this disease model. Behavioural tests showed a dramatically decreased number of asymmetric rotations in the intrastriatal Coenzyme Q10 group compared with the no treatment group. Rats with intrastriatal Coenzyme Q10 exposure also exhibited a larger number of dopaminergic neurons, higher expression of neurogenetic and angiogenetic factors, and less inflammation, and the effects were more prominent than those of orally administered Coenzyme Q10, although the dose of intrastriatal Coenzyme Q10 was 17,000-times lower than that of orally-administered Coenzyme Q10. Therefore, continuous, intrastriatal delivery of Coenzyme Q10, especially when combined with implantable devices for convection-enhanced delivery or deep brain stimulation, can be an effective strategy to prevent neurodegeneration in Parkinson's disease.
Collapse
Affiliation(s)
- Hyung Woo Park
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
- Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
| | - Chun Gwon Park
- Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea
- Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea
| | - Min Park
- Interdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seung Ho Lee
- Institute of Medical & Biological Engineering, Medical Research Center, Seoul National University, Seoul, 03080, Republic of Korea
| | - Hye Ran Park
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
- Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea
| | - Jaesung Lim
- Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Suwon, 16419, Republic of Korea
| | - Sun Ha Paek
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
- Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
| | - Young Bin Choy
- Interdisciplinary Program in Bioengineering, College of Engineering, Seoul National University, Seoul, 08826, Republic of Korea.
- Institute of Medical & Biological Engineering, Medical Research Center, Seoul National University, Seoul, 03080, Republic of Korea.
- Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
| |
Collapse
|
26
|
Narayanamurthy V, Jeroish ZE, Bhuvaneshwari KS, Bayat P, Premkumar R, Samsuri F, Yusoff MM. Advances in passively driven microfluidics and lab-on-chip devices: a comprehensive literature review and patent analysis. RSC Adv 2020; 10:11652-11680. [PMID: 35496619 PMCID: PMC9050787 DOI: 10.1039/d0ra00263a] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 02/20/2020] [Indexed: 12/15/2022] Open
Abstract
The development of passively driven microfluidic labs on chips has been increasing over the years. In the passive approach, the microfluids are usually driven and operated without any external actuators, fields, or power sources. Passive microfluidic techniques adopt osmosis, capillary action, surface tension, pressure, gravity-driven flow, hydrostatic flow, and vacuums to achieve fluid flow. There is a great need to explore labs on chips that are rapid, compact, portable, and easy to use. The evolution of these techniques is essential to meet current needs. Researchers have highlighted the vast potential in the field that needs to be explored to develop rapid passive labs on chips to suit market/researcher demands. A comprehensive review, along with patent analysis, is presented here, listing the latest advances in passive microfluidic techniques, along with the related mechanisms and applications.
Collapse
Affiliation(s)
- Vigneswaran Narayanamurthy
- Department of Electronics and Computer Engineering Technology, Faculty of Electrical and Electronic Engineering Technology, Universiti Teknikal Malaysia Melaka Hang Tuah Jaya 76100 Durian Tunggal Melaka Malaysia
- InnoFuTech No: 42/12, 7th Street, Vallalar Nagar Chennai Tamil Nadu 600072 India
- Centre of Excellence for Advanced Research in Fluid Flow, University Malaysia Pahang Kuantan 26300 Malaysia
| | - Z E Jeroish
- Department of Biomedical Engineering, Rajalakshmi Engineering College Chennai 602105 India
- Faculty of Electrical and Electronics Engineering, University Malaysia Pahang Pekan 26600 Malaysia
| | - K S Bhuvaneshwari
- Department of Biomedical Engineering, Rajalakshmi Engineering College Chennai 602105 India
- Faculty of Electronics and Computer Engineering, Universiti Teknikal Malaysia Melaka Hang Tuah Jaya 76100 Durian Tunggal Melaka Malaysia
| | - Pouriya Bayat
- Department of Bioengineering, McGill University Montreal QC Canada H3A 0E9
| | - R Premkumar
- Department of Biomedical Engineering, Rajalakshmi Engineering College Chennai 602105 India
| | - Fahmi Samsuri
- Faculty of Electrical and Electronics Engineering, University Malaysia Pahang Pekan 26600 Malaysia
| | - Mashitah M Yusoff
- Faculty of Industrial Sciences and Technology, University Malaysia Pahang Kuantan 26300 Malaysia
| |
Collapse
|
27
|
Hao B, Li W, Zhang S, Zhu Y, Li Y, Ding A, Huang X. A facile PEG/thiol-functionalized nanographene oxide carrier with an appropriate glutathione-responsive switch. Polym Chem 2020. [DOI: 10.1039/d0py00110d] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel nanographene oxide/PEG-based bioreduction-responsive smart drug delivery system with a GSH-responsive disulfide linker as the controlled release switch can selectively release anti-cancer drugs in cancer cells.
Collapse
Affiliation(s)
- Bingjie Hao
- Key Laboratory of Synthetic and Self-Assembly Chemistry for Organic Functional Molecules
- Center for Excellence in Molecular Synthesis
- Shanghai Institute of Organic Chemistry
- University of Chinese Academy of Sciences
- Chinese Academy of Sciences
| | - Wei Li
- Division of Physical Biology and Bioimaging Center
- Shanghai Synchrotron Radiation Facility
- Shanghai Institute of Applied Physics
- Chinese Academy of Sciences
- University of Chinese Academy of Sciences
| | - Sen Zhang
- Key Laboratory of Synthetic and Self-Assembly Chemistry for Organic Functional Molecules
- Center for Excellence in Molecular Synthesis
- Shanghai Institute of Organic Chemistry
- University of Chinese Academy of Sciences
- Chinese Academy of Sciences
| | - Ying Zhu
- Division of Physical Biology and Bioimaging Center
- Shanghai Synchrotron Radiation Facility
- Shanghai Institute of Applied Physics
- Chinese Academy of Sciences
- University of Chinese Academy of Sciences
| | - Yongjun Li
- Key Laboratory of Synthetic and Self-Assembly Chemistry for Organic Functional Molecules
- Center for Excellence in Molecular Synthesis
- Shanghai Institute of Organic Chemistry
- University of Chinese Academy of Sciences
- Chinese Academy of Sciences
| | - Aishun Ding
- Key Laboratory of Synthetic and Self-Assembly Chemistry for Organic Functional Molecules
- Center for Excellence in Molecular Synthesis
- Shanghai Institute of Organic Chemistry
- University of Chinese Academy of Sciences
- Chinese Academy of Sciences
| | - Xiaoyu Huang
- Key Laboratory of Synthetic and Self-Assembly Chemistry for Organic Functional Molecules
- Center for Excellence in Molecular Synthesis
- Shanghai Institute of Organic Chemistry
- University of Chinese Academy of Sciences
- Chinese Academy of Sciences
| |
Collapse
|
28
|
|
29
|
Zhang X, Li Y, Huang Z, Cui Y, Zhao Z, Yue X, Wang G, Liang R, Huang Y, Tan W, Wu C. Development and pharmacokinetics evaluation of quetiapine fumarate sustained-release tablets based on hydrophilic matrix. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101322] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
30
|
Coutant T, Laniesse D, Sykes JM. Advances in Therapeutics and Delayed Drug Release. Vet Clin North Am Exot Anim Pract 2019; 22:501-520. [PMID: 31395328 DOI: 10.1016/j.cvex.2019.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Reducing the frequency of drug administration in the treatment of exotic pets is advantageous because it may decrease handling frequency and thus potential stress and injury risk for the animal, increase owner compliance with the prescribed treatment, and decrease need for general anesthesia in patients that cannot be handled safely. Increasing efficient drug plasma concentration using sustained-released delivery systems is an appealing solution. Potential candidates that could provide a promising solution have been investigated in exotic pets. In this article, the technologies that are the closest to being integrated in exotic pet medicine are reviewed: osmotic pumps, nanoparticles, and hydrogels.
Collapse
Affiliation(s)
- Thomas Coutant
- Service NAC, CHV Fregis, 43 Avenue Aristide Briand, Arcueil 94110, France.
| | - Delphine Laniesse
- Eläinsairaala Evidensia Tammisto Vantaa, Tammiston Kauppatie 29, Vantaa 01510, Finland
| | - John M Sykes
- Wildlife Conservation Society, Zoological Health Program, 2300 Southern Boulevard, Bronx, NY 10460, USA
| |
Collapse
|
31
|
Yang Q, Yuan F, Xu L, Yan Q, Yang Y, Wu D, Guo F, Yang G. An Update of Moisture Barrier Coating for Drug Delivery. Pharmaceutics 2019; 11:pharmaceutics11090436. [PMID: 31480542 PMCID: PMC6781284 DOI: 10.3390/pharmaceutics11090436] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 08/13/2019] [Accepted: 08/16/2019] [Indexed: 02/03/2023] Open
Abstract
Drug hydrolytic degradation, caused by atmospheric and inherent humidity, significantly reduces the therapeutic effect of pharmaceutical solid dosages. Moisture barrier film coating is one of the most appropriate and effective approaches to protect the active pharmaceutical ingredients (API) from hydrolytic degradation during the manufacturing process and storage. Coating formulation design and process control are the two most commonly used strategies to reduce water vapor permeability to achieve the moisture barrier function. The principles of formulation development include designing a coating formulation with non-hygroscopic/low water activity excipients, and formulating the film-forming polymers with the least amount of inherent moisture. The coating process involves spraying organic or aqueous coating solutions made of natural or synthetic polymers onto the surface of the dosage cores in a drum or a fluid bed coater. However, the aqueous coating process needs to be carefully controlled to prevent hydrolytic degradation of the drug due to the presence of water during the coating process. Recently, different strategies have been designed and developed to effectively decrease water vapor permeability and improve the moisture barrier function of the film. Those strategies include newly designed coating formulations containing polymers with optimized functionality of moisture barrier, and newly developed dry coating processes that eliminate the usage of organic solvent and water, and could potentially replace the current solvent and aqueous coatings. This review aims to summarize the recent advances and updates in moisture barrier coatings.
Collapse
Affiliation(s)
- Qingliang Yang
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China
| | - Feng Yuan
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
| | - Lei Xu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
| | - Qinying Yan
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China
| | - Yan Yang
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China
| | - Danjun Wu
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China
| | - Fangyuan Guo
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China
| | - Gensheng Yang
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
- Research Institute of Pharmaceutical Particle Technology, Zhejiang University of Technology, Hangzhou 310014, China.
| |
Collapse
|
32
|
Thakur N, Sharma B, Bishnoi S, Jain S, Nayak D, Sarma TK. Biocompatible Fe3+ and Ca2+ Dual Cross-Linked G-Quadruplex Hydrogels as Effective Drug Delivery System for pH-Responsive Sustained Zero-Order Release of Doxorubicin. ACS APPLIED BIO MATERIALS 2019; 2:3300-3311. [DOI: 10.1021/acsabm.9b00334] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Neha Thakur
- Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore 453552, India
| | - Bhagwati Sharma
- Materials Research Centre, Malaviya National Institute of Technology Jaipur, Jaipur 302017, India
| | - Suman Bishnoi
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore 453552, India
| | - Siddarth Jain
- Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore 453552, India
| | - Debasis Nayak
- Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore 453552, India
| | - Tridib K. Sarma
- Discipline of Chemistry, Indian Institute of Technology Indore, Simrol, Khandwa Road, Indore 453552, India
| |
Collapse
|
33
|
Caille S, Allgeier AM, Bernard C, Correll TL, Cosbie A, Crockett RD, Cui S, Faul MM, Hansen KB, Huggins S, Langille N, Mennen SM, Morgan BP, Morrison H, Muci A, Nagapudi K, Quasdorf K, Ranganathan K, Roosen P, Shi X, Thiel OR, Wang F, Tvetan JT, Woo JCS, Wu S, Walker SD. Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00200] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Seb Caille
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alan M. Allgeier
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Charles Bernard
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tiffany L. Correll
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Andrew Cosbie
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Richard D. Crockett
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sheng Cui
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Margaret M. Faul
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Karl B. Hansen
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Seth Huggins
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Neil Langille
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Steven M. Mennen
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Bradley P. Morgan
- Research & Nonclinical Development, Cytokinetics, 280 East Grand Avenue, South San Francisco, California 94080, United States
| | - Henry Morrison
- Drug Product Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Alexander Muci
- Research & Nonclinical Development, Cytokinetics, 280 East Grand Avenue, South San Francisco, California 94080, United States
| | - Karthik Nagapudi
- Drug Product Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Kyle Quasdorf
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Krishnakumar Ranganathan
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Philipp Roosen
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Xianqing Shi
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Oliver R. Thiel
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Fang Wang
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Justin T. Tvetan
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jacqueline C. S. Woo
- Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Steven Wu
- Attribute Sciences, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Shawn D. Walker
- Drug Substance Technologies, Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
34
|
Pons-Faudoa FP, Ballerini A, Sakamoto J, Grattoni A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices 2019; 21:47. [PMID: 31104136 PMCID: PMC7161312 DOI: 10.1007/s10544-019-0389-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.
Collapse
Affiliation(s)
- Fernanda P Pons-Faudoa
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- School of Medicine and Health Sciences, Tecnologico de Monterrey, Avenida Eugenio Garza Sada 2501, 64849, Monterrey, NL, Mexico
| | - Andrea Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- Department of Oncology and Onco-Hematology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Jason Sakamoto
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.
- Department of Surgery, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
- Department of Radiation Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
| |
Collapse
|
35
|
Chen Z, Zhu Q, Qi J, Lu Y, Wu W. Sustained and controlled release of herbal medicines: The concept of synchronized release. Int J Pharm 2019; 560:116-125. [DOI: 10.1016/j.ijpharm.2019.01.074] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 01/31/2019] [Accepted: 01/31/2019] [Indexed: 10/27/2022]
|
36
|
|
37
|
Chen L, Yang G, Chu X, Gao C, Wang Y, Gong W, Li Z, Yang Y, Yang M, Gao C. Polymer Distribution and Mechanism Conversion in Multiple Media of Phase-Separated Controlled-Release Film-Coating. Pharmaceutics 2019; 11:pharmaceutics11020080. [PMID: 30769846 PMCID: PMC6410001 DOI: 10.3390/pharmaceutics11020080] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 01/30/2019] [Accepted: 02/03/2019] [Indexed: 01/04/2023] Open
Abstract
Phase-separated films of water-insoluble ethyl cellulose (EC) and water-soluble hydroxypropyl cellulose (HPC) can be utilized to tailor drug release from coated pellets. In the present study, the effects of HPC levels and the pH, type, ionic strength and osmolarity of the media on the release profiles of soluble metoprolol succinates from the EC/HPC-coated pellets were investigated, and the differences in drug-release kinetics in multiple media were further elucidated through the HPC leaching and swelling kinetics of the pellets, morphology (SEM) and water uptake of the free films and the interaction between the coating polymers and the media compositions. Interestingly, the drug release rate from the pellets in different media was not in agreement with the drug solubility which have a positive correlation with the drug dissolution rate based on Noyes–Whitney equation law. In particular, the drug release rate in acetate buffer at pH 4.5 was faster than that in other media despite the solubility of drug was relatively lower, regardless of the HPC levels. It may be attributed to the mutual effect between the EC and acetate buffer, which improved the permeability of the film. In contrast, the release of drug in HCl solution was dependent on the HPC levels. Increasing the levels of HPC increased the effects of hydrogen ions on the polymer of HPC, which resulted in a lower viscosity and strength of the gel, forming the larger size of pores in polymer films, thus increasing the drug diffused from the coating film. Further findings in phosphate buffer showed a reduction in the drug release compared to that in other media, which was only sensitive to the osmolarity rather than the HPC level and pH of the buffer. Additionally, a mathematical theory was used to better explain and understand the experimentally measured different drug release patterns. In summary, the study revealed that the effects of the media overcompensated that of the drug solubility to some extent for controlled-release of the coating polymers, and the drug release mechanism in multiple media depend on EC and HPC rather than on HPC alone, which may have a potential to facilitate the optimization of ideally film-coated formulations.
Collapse
Affiliation(s)
- Lu Chen
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Guobao Yang
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Xiaoyang Chu
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Chunhong Gao
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Yuli Wang
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Wei Gong
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Zhiping Li
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Yang Yang
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Meiyan Yang
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| | - Chunsheng Gao
- State key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
| |
Collapse
|
38
|
Stewart SA, Domínguez-Robles J, Donnelly RF, Larrañeta E. Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers (Basel) 2018; 10:E1379. [PMID: 30961303 PMCID: PMC6401754 DOI: 10.3390/polym10121379] [Citation(s) in RCA: 182] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 12/10/2018] [Indexed: 12/27/2022] Open
Abstract
The oral route is a popular and convenient means of drug delivery. However, despite its advantages, it also has challenges. Many drugs are not suitable for oral delivery due to: first pass metabolism; less than ideal properties; and side-effects of treatment. Additionally, oral delivery relies heavily on patient compliance. Implantable drug delivery devices are an alternative system that can achieve effective delivery with lower drug concentrations, and as a result, minimise side-effects whilst increasing patient compliance. This article gives an overview of classification of these drug delivery devices; the mechanism of drug release; the materials used for manufacture; the various methods of manufacture; and examples of clinical applications of implantable drug delivery devices.
Collapse
Affiliation(s)
- Sarah A Stewart
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Juan Domínguez-Robles
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Ryan F Donnelly
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Eneko Larrañeta
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
| |
Collapse
|
39
|
Davoodi P, Lee LY, Xu Q, Sunil V, Sun Y, Soh S, Wang CH. Drug delivery systems for programmed and on-demand release. Adv Drug Deliv Rev 2018; 132:104-138. [PMID: 30415656 DOI: 10.1016/j.addr.2018.07.002] [Citation(s) in RCA: 185] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 05/25/2018] [Accepted: 07/02/2018] [Indexed: 01/06/2023]
Abstract
With the advancement in medical science and understanding the importance of biodistribution and pharmacokinetics of therapeutic agents, modern drug delivery research strives to utilize novel materials and fabrication technologies for the preparation of robust drug delivery systems to combat acute and chronic diseases. Compared to traditional drug carriers, which could only control the release of the agents in a monotonic manner, the new drug carriers are able to provide a precise control over the release time and the quantity of drug introduced into the patient's body. To achieve this goal, scientists have introduced "programmed" and "on-demand" approaches. The former provides delivery systems with a sophisticated architecture to precisely tune the release rate for a definite time period, while the latter includes systems directly controlled by an operator/practitioner, perhaps with a remote device triggering/affecting the implanted or injected drug carrier. Ideally, such devices can determine flexible release pattern and intensify the efficacy of a therapy via controlling time, duration, dosage, and location of drug release in a predictable, repeatable, and reliable manner. This review sheds light on the past and current techniques available for fabricating and remotely controlling drug delivery systems and addresses the application of new technologies (e.g. 3D printing) in this field.
Collapse
|
40
|
Sanjay ST, Zhou W, Dou M, Tavakoli H, Ma L, Xu F, Li X. Recent advances of controlled drug delivery using microfluidic platforms. Adv Drug Deliv Rev 2018; 128:3-28. [PMID: 28919029 PMCID: PMC5854505 DOI: 10.1016/j.addr.2017.09.013] [Citation(s) in RCA: 174] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Revised: 08/11/2017] [Accepted: 09/13/2017] [Indexed: 12/13/2022]
Abstract
Conventional systematically-administered drugs distribute evenly throughout the body, get degraded and excreted rapidly while crossing many biological barriers, leaving minimum amounts of the drugs at pathological sites. Controlled drug delivery aims to deliver drugs to the target sites at desired rates and time, thus enhancing the drug efficacy, pharmacokinetics, and bioavailability while maintaining minimal side effects. Due to a number of unique advantages of the recent microfluidic lab-on-a-chip technology, microfluidic lab-on-a-chip has provided unprecedented opportunities for controlled drug delivery. Drugs can be efficiently delivered to the target sites at desired rates in a well-controlled manner by microfluidic platforms via integration, implantation, localization, automation, and precise control of various microdevice parameters. These features accordingly make reproducible, on-demand, and tunable drug delivery become feasible. On-demand self-tuning dynamic drug delivery systems have shown great potential for personalized drug delivery. This review presents an overview of recent advances in controlled drug delivery using microfluidic platforms. The review first briefly introduces microfabrication techniques of microfluidic platforms, followed by detailed descriptions of numerous microfluidic drug delivery systems that have significantly advanced the field of controlled drug delivery. Those microfluidic systems can be separated into four major categories, namely drug carrier-free micro-reservoir-based drug delivery systems, highly integrated carrier-free microfluidic lab-on-a-chip systems, drug carrier-integrated microfluidic systems, and microneedles. Microneedles can be further categorized into five different types, i.e. solid, porous, hollow, coated, and biodegradable microneedles, for controlled transdermal drug delivery. At the end, we discuss current limitations and future prospects of microfluidic platforms for controlled drug delivery.
Collapse
Affiliation(s)
- Sharma T. Sanjay
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
| | - Wan Zhou
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
| | - Maowei Dou
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory
| | - Hamed Tavakoli
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
| | - Lei Ma
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
| | - Feng Xu
- Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an 710049, P.R. China
| | - XiuJun Li
- Department of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
- Border Biomedical Research Center, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
- Biomedical Engineering, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
- Environmental Science and Engineering, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA, Richland, Washington, 99354, USA
| |
Collapse
|
41
|
Taguchi K, Bessho N, Hasegawa M, Narimatsu H, Matsumoto T, Kobayashi T. Co-treatment with clonidine and a GRK2 inhibitor prevented rebound hypertension and endothelial dysfunction after withdrawal in diabetes. Hypertens Res 2018; 41:263-274. [DOI: 10.1038/s41440-018-0016-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 09/28/2017] [Accepted: 11/17/2017] [Indexed: 12/25/2022]
|
42
|
Naveen NR, Gopinath C, Rao DS. Design expert supported mathematical optimization of repaglinide gastroretentive floating tablets: In vitro and in vivo evaluation. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2017. [DOI: 10.1016/j.fjps.2017.05.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
43
|
Zhang P, Zhang L, Chen H, Dong Z, Zhang D. Surfaces Inspired by the Nepenthes Peristome for Unidirectional Liquid Transport. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2017; 29. [PMID: 28782892 DOI: 10.1002/adma.201702995] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 06/23/2017] [Indexed: 05/15/2023]
Abstract
The slippery peristome of the pitcher plant Nepenthes has attracted much attention due to its unique function for preying on insects. Recent findings on the peristome surface of Nepenthes alata demonstrate a fast and continuous unidirectional liquid transport, which is enabled by the combination of a pinning effect at the sharp edges and a capillary rise in the wedge, deriving from the multiscale structure, which provides inspiration for designing and fabricating functional surfaces for unidirectional liquid transport. Developments in the fabrication methods of peristome-inspired surfaces and control methods for liquid transport are summarized. Both potential applications in the fields of microfluidic devices, biomedicine, and mechanical engineering and directions for further research in the future are discussed.
Collapse
Affiliation(s)
- Pengfei Zhang
- School of Mechanical Engineering and Automation, Beihang University, Beijing, 100191, China
| | - Liwen Zhang
- School of Mechanical Engineering and Automation, Beihang University, Beijing, 100191, China
| | - Huawei Chen
- School of Mechanical Engineering and Automation, Beihang University, Beijing, 100191, China
| | - Zhichao Dong
- CAS Key Laboratory of Bio-inspired Materials and Interfacial Science, CAS Center for Excellence in Nanoscience, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
| | - Deyuan Zhang
- School of Mechanical Engineering and Automation, Beihang University, Beijing, 100191, China
| |
Collapse
|
44
|
Amaraneni M, Pang J, Bruckner JV, Muralidhara S, Mortuza TB, Gullick D, Hooshfar S, White CA, Cummings BS. Influence of Maturation on In Vivo Tissue to Plasma Partition Coefficients for Cis - and Trans -Permethrin. J Pharm Sci 2017; 106:2144-2151. [DOI: 10.1016/j.xphs.2017.04.024] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 04/13/2017] [Accepted: 04/13/2017] [Indexed: 01/14/2023]
|
45
|
Comtet J, Jensen KH, Turgeon R, Stroock AD, Hosoi AE. Passive phloem loading and long-distance transport in a synthetic tree-on-a-chip. NATURE PLANTS 2017; 3:17032. [PMID: 28319082 DOI: 10.1038/nplants.2017.32] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Accepted: 02/14/2017] [Indexed: 06/06/2023]
Abstract
Vascular plants rely on differences in osmotic pressure to export sugars from regions of synthesis (mature leaves) to sugar sinks (roots, fruits). In this process, known as Münch pressure flow, the loading of sugars from photosynthetic cells to the export conduit (the phloem) is crucial, as it sets the pressure head necessary to power long-distance transport. Whereas most herbaceous plants use active mechanisms to increase phloem sugar concentration above that of the photosynthetic cells, in most tree species, for which transport distances are largest, loading seems, counterintuitively, to occur by means of passive symplastic diffusion from the mesophyll to the phloem. Here, we use a synthetic microfluidic model of a passive loader to explore the non-linear dynamics that arise during export and determine the ability of passive loading to drive long-distance transport. We first demonstrate that in our device, the phloem concentration is set by the balance between the resistances to diffusive loading from the source and convective export through the phloem. Convection-limited export corresponds to classical models of Münch transport, where the phloem concentration is close to that of the source; in contrast, diffusion-limited export leads to small phloem concentrations and weak scaling of flow rates with hydraulic resistance. We then show that the effective regime of convection-limited export is predominant in plants with large transport resistances and low xylem pressures. Moreover, hydrostatic pressures developed in our synthetic passive loader can reach botanically relevant values as high as 10 bars. We conclude that passive loading is sufficient to drive long-distance transport in large plants, and that trees are well suited to take full advantage of passive phloem loading strategies.
Collapse
Affiliation(s)
- Jean Comtet
- MIT Mechanical Engineering, Cambridge, Massachusetts 02139, USA
| | - Kaare H Jensen
- Department of Physics, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark
| | - Robert Turgeon
- Section of Plant Biology, Cornell University, Ithaca, New York 14853, USA
| | - Abraham D Stroock
- School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York 14853, USA
- Kavli Institute at Cornell for Nanoscale Science, Cornell University, Ithaca, New York 14853, USA
| | - A E Hosoi
- MIT Mechanical Engineering, Cambridge, Massachusetts 02139, USA
| |
Collapse
|
46
|
Soft Plant Robotic Solutions: Biological Inspiration and Technological Challenges. EMERGENCE, COMPLEXITY AND COMPUTATION 2017. [DOI: 10.1007/978-3-319-33921-4_27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
47
|
Abstract
Systemic application of therapeutics to the CNS tissue often results in subtherapeutic drug levels, because of restricted and selective penetration through the blood-brain barrier (BBB). Here, we give a detailed description of a standardized technique for intrathecal drug delivery in rodents, analogous to the technique used in humans. The intrathecal drug delivery method bypasses the BBB and thereby offers key advantages over oral or intravenous administration, such as maximized local drug doses with minimal systemic side effects. We describe how to deliver antibodies or drugs over several days or weeks from a s.c. minipump and a fine catheter inserted into the subdural space over the spinal cord (20 min operative time) or into the cisterna magna (10 min operative time). Drug levels can be sampled by quick and minimally invasive cerebrospinal fluid (CSF) collection from the cisterna magna (5 min procedure time). These techniques enable targeted application of any compound to the CNS for therapeutic studies in a wide range of CNS disease rodent models. Basic surgery skills are helpful for carrying out the procedures described in this protocol.
Collapse
|
48
|
Abstract
Drug delivery as a strategy to improve the effect of therapeutic treatment is gaining tremendous interest in biomedical research. The recent advancement in microfluidic technique designed to precisely control the liquid at micro or nano liter level has shed some new lights on reshaping the ongoing drug delivery research. In this aspect, this present mini-review gives an overview on the potential applications of microfluidic technique in the area of drug delivery, which basically covers the fabrication of drug delivery carriers and the design of microfluidic-based smart systems for localized in vivo drug delivery.
Collapse
Affiliation(s)
- Wenjian Guan
- Department of Chemical Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, US
| | - Yi Zhang
- School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, 30332-0100, US
| |
Collapse
|
49
|
Xie X, Yang Y, Yang Y, Li Z, Zhang H, Chi Q, Cai X, Mei X. The development and evaluation of a subcutaneous infusion delivery system based on osmotic pump control and gas drive. Drug Deliv 2016; 23:2193-2204. [PMID: 25188841 DOI: 10.3109/10717544.2014.955617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A novel, self-administration drug delivery system for subcutaneous infusion was developed and evaluated. The device includes two main components: an osmotic tablet controlled gas actuator and a syringe catheter system. The sodium carbonate in the osmotic pump tablet will release into the surround citric acid solution and produce CO2 gas, which will drive the drug solution into subcutaneous tissue. The key formulation factors of the osmotic tablet that would influence the infusion profiles of the device were investigated by single factor exploration. The formulation was optimized via a response surface methodology. With an 18 ± 4 min of lag time, the delivery system was able to infuse at an approximate zero-order up to 5.90 ± 0.37 h with a precision of 9.0% RSD (n = 6). A linear correlation was found for the infusion profile and the fitting equation was Y = 0.014X - 0.004 (r = 0.998). A temperature change of 4 °C was found to modify the flow rate by about 12.0%. In vivo results demonstrated that the present subcutaneous infusion device was similar to the commercial infusion pump, and it could bring a long and constant ampicillin plasma level with minimized fluctuations.
Collapse
Affiliation(s)
- Xiangyang Xie
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China.,b Department of Pharmacy , Wuhan General Hospital of Guangzhou Military Command , Wuhan , PR China , and
| | - Yang Yang
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| | - Yanfang Yang
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| | - Zhiping Li
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| | - Hui Zhang
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| | - Qiang Chi
- c Department of Pharmacy , The 215th Clinic of 406th Hospital of the Chinese People's Liberation Army , Dalian , China
| | - Xingshi Cai
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| | - Xingguo Mei
- a Department of Pharmaceutics , Beijing Institute of Pharmacology and Toxicology , Beijing , PR China
| |
Collapse
|
50
|
Three dimensional structural insight of laser drilled orifices in osmotic pump tablets. Eur J Pharm Sci 2016; 93:287-94. [DOI: 10.1016/j.ejps.2016.08.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 08/17/2016] [Accepted: 08/20/2016] [Indexed: 11/20/2022]
|